Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Developing a multisectoral National Action Plan for Health Security (NAPHS) to implement the International Health Regulations (IHR 2005) in Tanzania.

Mghamba JM, Talisuna AO, Suryantoro L, Saguti GE, Muita M, Bakari M, Rusibamayila N, Ally M, Bernard J, Banda R, Mapunda M, Eidex R, Sreedharan R, Sliter K, Nikkari S, Saikat S, Lolong GPM, Verboom P, Yahaya AA, Chungong S, Rodier G, Fall IS.

BMJ Glob Health. 2018 Mar 9;3(2):e000600. doi: 10.1136/bmjgh-2017-000600. eCollection 2018. Review.

2.

Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries.

Stenberg K, Hanssen O, Edejer TT, Bertram M, Brindley C, Meshreky A, Rosen JE, Stover J, Verboom P, Sanders R, Soucat A.

Lancet Glob Health. 2017 Sep;5(9):e875-e887. doi: 10.1016/S2214-109X(17)30263-2. Epub 2017 Jul 17.

3.

The cost utility of solifenacin in the treatment of overactive bladder.

Hakkaart L, Verboom P, Phillips R, Al MJ.

Int Urol Nephrol. 2009;41(2):293-8. doi: 10.1007/s11255-008-9448-2. Epub 2008 Aug 15.

PMID:
18704742
4.

Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use.

Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, Vos MC.

J Antimicrob Chemother. 2008 Feb;61(2):428-35. Epub 2007 Dec 21.

PMID:
18156278
5.

Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.

Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ; POORT Study Group.

J Clin Oncol. 2006 Apr 20;24(12):1800-6. Epub 2006 Mar 27.

PMID:
16567772
6.

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.

Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM.

Vaccine. 2005 Mar 18;23(17-18):2379-87.

PMID:
15755632
7.

The cost effectiveness of Apligraf treatment of diabetic foot ulcers.

Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z.

Pharmacoeconomics. 2003;21(16):1171-83.

PMID:
14594438
8.

Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.

Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, van Mourik JC, Postmus PE, Boers M, Grijseels EW, Teule GJ, Uyl-de Groot CA; PLUS study group.

Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1444-9. Epub 2003 May 29.

PMID:
14579081
9.

Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.

Verboom P, Herder GJ, Hoekstra OS, Smit EF, van den Bergh JH, van Velthoven PC, Grijseels EW.

Int J Technol Assess Health Care. 2002 Summer;18(3):576-85.

PMID:
12391950
10.

The cost of atopic dermatitis in the Netherlands: an international comparison.

Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F.

Br J Dermatol. 2002 Oct;147(4):716-24. Review.

PMID:
12366418
11.

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, Teule GJ.

Lancet. 2002 Apr 20;359(9315):1388-93.

PMID:
11978336
12.

Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.

Herder GJ, Verboom P, Smit EF, van Velthoven PC, van den Bergh JH, Colder CD, van Mansom I, van Mourik JC, Postmus PE, Teule GJ, Hoekstra OS.

Thorax. 2002 Jan;57(1):11-4.

13.

The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.

Hakkaart-van Roijen L, Verboom P, Redekop WK, Touw KR, Rutten FF.

Pharmacoeconomics. 2001;19(5 Pt 2):599-608.

PMID:
11465304
14.

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.

Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY.

Br J Dermatol. 2001 May;144(5):967-72.

PMID:
11359382
15.

Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography.

van Tinteren H, Hoekstra OS, Smit EF, Verboom P, Boers M; PLUS Study Group.

Control Clin Trials. 2001 Feb;22(1):89-98.

PMID:
11165427

Supplemental Content

Loading ...
Support Center